Exact Sciences targets other cancers

Exact Sciences Corp., the fast-growing Madison company that developed and manufactures Cologuard, an at-home stool test for colon cancer, is targeting more than a dozen other deadly cancers, according to a report in the Wisconsin State Journal.

Currently, the company is processing 3 million tests a year, and when a second lab is completed, its capacity will more than double to about 7 million per year.

A diagnostic blood test for colon cancer is also being developed, as well as blood tests for 15 other deadly cancers. In years to come, the company, together with partners at Mayo Clinic, hope to develop one universal blood test capable of screening for a variety of cancers.